Technology born from world-class nanoscience

Disruptive Pharma is rooted in nanoscience research conducted at Uppsala University, where work led by Professor Maria Strömme resulted in the discovery of a novel nanostructured, amorphous magnesium carbonate material (MMC).

A first patent application was filed in 2012, forming the basis for Disruptive Materials. To fully focus on pharmaceutical applications, Disruptive Pharma was established in 2021 as a spin-out, dedicated to developing and commercializing the Formulite™ technology platform.

Today, Disruptive Pharma focuses on applying the Formulite^™platform to develop added-value oral drug products and support pharmaceutical partners in overcoming bioavailability challenges. The company combines a selective pipeline of in-house programs with co-development partnering across multiple therapeutic areas.

A new phase of growth

Disruptive Pharma has entered a new phase of development. With Formulite^™now clinically validated in humans, our platform is scientifically robust, regulatorily anchored, and commercially relevant. This milestone marks our transition from a technology-driven development company to a growth-oriented pharmaceutical partner.

We focus on improving oral bioavailability for small molecules and selected peptides, addressing a persistent industry challenge through a clinically validated, cost-efficient and environmentally considerate formulation approach.

Our dual business model combines tailored Partnering and Co-Development projects with the advancement of selected product candidates based on established APIs. Together, these activities position Disruptive Pharma as a preferred partner for companies seeking to unlock additional clinical and commercial value from existing drug assets.

With growing interest from pharma, biotech and manufacturing partners, and a strengthened financial base, we see strong potential for continued value creation through partnerships, licensing and long-term collaboration.